LOGO
LOGO

COVID-19: Drugs in Development

The COVID-19 outbreak, which started in December 2019 in Wuhan City, China, was declared a "Public Health Emergency of International Concern" by the WHO on January 30, 2020. The outbreak was characterized as a pandemic on March 11, 2020.

Currently, there are no drugs to treat COVID-19, caused by the novel coronavirus SARS-CoV-2.

Listed below are companies that are in the race to find a treatment or vaccine for the novel coronavirus.

Subscribe to RTT Intelligent Investor for FREE 7-Day Trial with complete access to COVID-19 Drugs in Development Calendar.

Company Name
Drug
Current Stage
Next Milestone
Collaboration
Last Updated
Imunon, Inc.
(IMNN)
IMNN-101- COVID-19 booster vaccine candidate
Completed a first-in-human study of COVID-19 booster vaccine candidate IMNN-101- reported on May 11, 2026.

Completed dosing in a first-in-human study of COVID-19 booster vaccine candidate IMNN-101- reported on May 5, 2026.
-
-
08/12/2026
BioNTech SE
(BNTX)
XFG-adapted COVID-19 Vaccine
European Commission (EC) has granted marketing authorization for 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, for individuals 6 months of age and older- reported on July 29, 2026.
-
Pfizer
08/03/2026
Invivyd, Inc.
(IVVD)
PEMGARDA
The FDA has issued a notice terminating the Emergency Use Authorization for PEMGARDA, effective June 29, 2027- reported on July 6, 2026.

Positive, continued, and clinically meaningful in vitro neutralization data for PEMGARDA against the currently dominant LP.8.1 variant of SARS-CoV-2 were reported on March 05, 2025.
-
-
07/27/2026
Organon & Co.
(OGN)
Tofidence
The FDA approved expanded indication for Tofidence, a biosimilar to Actemra, to include hospitalized patients aged 2 years and older with COVID-19- reported on Jun 10, 2026.
-
-
07/13/2026
Invivyd, Inc.
(IVVD)
VYD2311
Initiated LIBERTY Phase 3 study evaluating VYD2311, against a standard mRNA COVID-19 vaccine- reported on June 9, 2026.

Enrollment in Phase 3 DECLARATION study of VYD2311 for preventing symptomatic COVID-19 was completed- reported on June 1, 2026.

Positive data from Phase 1/2 study of VYD2311, designed as Covid-19 vaccine as well as treatment, were reported on Feb.3, 2025.

Phase 1 study of VYD2311 for the treatment of Covid-19 was initiated- reported on Sept. 04, 2024
Topline data from the LIBERTY trial expected in Q3 2026.

Top-line results from DECLARATION study are expected in late third quarter 2026.

Preliminary data readouts from the Phase 1 trial expected in the fourth quarter of 2024
-
07/13/2026
Vaxart, Inc.
(VXRT)
Oral tablet COVID-19 vaccine Candidate
Positive 12-month topline results from sentinel safety cohort of its Phase 2b study of oral pill COVID-19 vaccine candidate were reported on July 6, 2026.

DSMB has recommended that the Phase 2b study of Vaxart’s oral pill COVID-19 vaccine candidate to continue without any modifications- reported on Jan. 13, 2025.
Full trial readout is anticipated in 2027.

Topline data from sentinel cohort of the Phase 2b trial anticipated in the second quarter of 2026.
-
07/13/2026
Shionogi & Co., Ltd.
Ensitrelvir (S-217622)
The FDA approved ensitrelvir for post-exposure prophylaxis of COVID-19 in adults and adolescents 12 years of age and older- reported on June 1, 2026.

The FDA has accepted NDA for ensitrelvir proposed for the prevention of COVID-19 following exposure to an infected individual.

Phase 3 portion of Phase 2/3 SCORPIO-SR study in patients with mild to moderate COVID-19 met its primary goal- reported on Feb.9, 2024.
-
-
06/03/2026

Get Full Access to latest records of COVID-19 Drugs in Development Calendar by subscribing to RTT Intelligent Investor with FREE 7-Day Trial. (No Credit Card Required)

Buy this Content
3 Widely Used Medicines Classified as Carcinogenic by WHO’s Cancer Research Agency

August 13, 2026 05:33 ET
The World Health Organization’s cancer research agency, the International Agency for Research on Cancer (IARC), has classified three widely used medicines as carcinogenic to humans.

View More Videos
Slide Shows
Biotech Stocks Facing FDA Decision In August 2026

Biotech Stocks Facing FDA Decision In August 2026
Biotech Stocks Facing FDA Decision In July 2026

Biotech Stocks Facing FDA Decision In July 2026
Biotech Stocks Facing FDA Decision In June 2026

Biotech Stocks Facing FDA Decision In June 2026
Latest Updates on COVID-19
View More
Editors Pick
tesla 24082026 lt

Tesla Recalls 3 Mln Cars In China Over Hidden Door Handles; Shares Drop

August 24, 2026 09:51 ET
wallmart 20082026 lt

Walmart Stock Drops On Weak Q2 Profit, Slower U.S. Comps Growth, Despite Positive Outlook

August 20, 2026 08:43 ET
targetcorp1 19082026 lt

Target Lifts FY26 Outlook After Q2 Profit Growth On Tariff Benefit, Comps

August 19, 2026 08:30 ET
homedepot 18082026 lt

Home Depot Q2 Results Rise, Backs FY26 View; Expands Express Delivery

August 18, 2026 09:36 ET
Copyright © 2026 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us   |   Contact Us   |   Privacy   |   Sitemap